Zolbetuximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric |
| Target | CLDN18.2 |
| Clinical data | |
| Trade names | Vyloy |
| Other names | IMAB362; Claudiximab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Zolbetuximab (development code IMAB362) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1] Astellas Pharmaceuticals acquired the rights to zolbetuximab in December, 2016 when it acquired Ganymed Pharmaceuticals. [2]
The drug was in phase III clinical trials as of November 2021[update] for gastric cancer.[3][4][5][6]
In Japan, zolbetuximab is approved for the treatment of patients with CLDN18.2-positive, unresectable, advanced or recurrent gastric cancer.[7]
References
- ^ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". www.ganymed-pharmaceuticals.de.
- ^ "Astellas Completes Acquisition of Ganymed Pharmaceuticals". Astellas Pharma Inc.
- ^ Clinical trial number NCT03653507 for "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)" at ClinicalTrials.gov
- ^ Clinical trial number NCT03504397 for "A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)" at ClinicalTrials.gov
- ^ Shitara K, Lordick F, Bang YJ, Enzinger PC, Ilson DH, Shah MA, et al. (2023-01-19). "Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study". J Clin Oncol. 41 (suppl 4): abstr LBA292. doi:10.1200/JCO.2023.41.3_suppl.LBA292 (inactive 31 January 2024). Retrieved 2023-02-07.
{{cite journal}}: CS1 maint: DOI inactive as of January 2024 (link) - ^ "Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium".
- ^ "Japan's MHLW Approves Zolbetuximab in CLDN18.2-Positive Gastric Cancer". onclive.com. March 26, 2024.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- CS1 maint: DOI inactive as of January 2024
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Articles containing potentially dated statements from November 2021
- All articles containing potentially dated statements
- Monoclonal antibodies
- Antineoplastic drugs
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs